lsc-webmaster

BlueSphere Bio to Present Corporate Update and Participate in a Panel Discussion at the 2024 BIO International Convention

PITTSBURGH, May 30, 2024 (GLOBE NEWSWIRE) — BlueSphere Bio, a drug development company focused on the discovery of novel T-cell receptor (TCR)-based therapies with a robust clinical pipeline and powerful, high-throughput TCR identification and screening platform, TCXpress™, today announced that Keir Loiacono, Esq., Chief Executive Officer of BlueSphere Bio, will provide a corporate update and […]

BlueSphere Bio to Present Corporate Update and Participate in a Panel Discussion at the 2024 BIO International Convention Read More »

BlueSphere Bio to Present a Corporate Overview at the 2022 BIO International Convention

PITTSBURGH, PA, June 13, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced that David Apelian, M.D., Ph.D., MBA, Chief Executive Officer of BlueSphere Bio, will provide a corporate overview at the 2022

BlueSphere Bio to Present a Corporate Overview at the 2022 BIO International Convention Read More »

BlueSphere Bio Presents New Data Supporting the Potential of its TCXpress™ Platform at the 2022 AACR Meeting

TCXpress™ identified a diverse set of novel T-cell receptors (TCRs) with in vitro reactivity against the minor histocompatibility antigen HA-1, from a single donor Data support the broad potential of TCXpress™ to rapidly and efficiently identify TCRs with activity against a selected target PITTSBURGH, PA, April 8, 2022 — BlueSphere Bio, a T-cell receptor (TCR)

BlueSphere Bio Presents New Data Supporting the Potential of its TCXpress™ Platform at the 2022 AACR Meeting Read More »

BlueSphere Bio to Present at the BIO CEO & Investor Conference

PITTSBURGH, PA, February 8, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a revolutionary TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced that David Apelian, M.D., Ph.D., MBA, chief executive officer of BlueSphere Bio, will present an in-person company overview at the

BlueSphere Bio to Present at the BIO CEO & Investor Conference Read More »

BlueSphere Bio appoints industry veteran Jonathan Peacock as Chairman of the Board

Today BlueSphere Bio announces the appointment of Jonathan Peacock as Chairman of the Board of Directors in its pursuit to build an industry leading Board and executive team to develop their groundbreaking immune oncology T cell receptor (TCR) T-cell discovery platform and clinical programs. Mr. Peacock brings a wealth of experience from the biotech and

BlueSphere Bio appoints industry veteran Jonathan Peacock as Chairman of the Board Read More »